1. Home >
  2. M&A >
  3. Divestiture >
  4. United States >
  5. Pennsylvania >
  6. Strongbridge Biopharma Acquires Taro Pharmaceutical Industries - U.S. Rights to KEVEYIS

M&A Deal Summary

Strongbridge Biopharma Acquires Taro Pharmaceutical Industries - U.S. Rights to KEVEYIS

On December 23, 2016, Strongbridge Biopharma acquired life science company Taro Pharmaceutical Industries - U.S. Rights to KEVEYIS from Taro Pharmaceutical Industries for 9M USD

Acquisition Highlights
  • This is Strongbridge Biopharma’s 1st transaction in the Life Science sector.
  • This is Strongbridge Biopharma’s largest (disclosed) transaction.
  • This is Strongbridge Biopharma’s 1st transaction in the United States.
  • This is Strongbridge Biopharma’s 1st transaction in Pennsylvania.

M&A Deal Summary
Date 2016-12-23
Target Taro Pharmaceutical Industries - U.S. Rights to KEVEYIS
Sector Life Science
Buyer(s) Strongbridge Biopharma
Sellers(s) Taro Pharmaceutical Industries
Deal Type Divestiture
Deal Value 9M USD

Target

Taro Pharmaceutical Industries - U.S. Rights to KEVEYIS

Trevose, Pennsylvania, United States
Taro Pharmaceutical Industries Ltd. - U.S. Rights to KEVEYIS (dichlorphenamide) is indicated for the treatment of primary hyperkalemic periodic paralysis, primary hypokalemic periodic paralysis, and related variants.

Search 214,239 Deals Now

SEARCH BY

  • Buyer Type (PE or Strategic)
  • Deal Size ($10M to $10B+)
  • Sector (60 Sectors)
  • Deal Type
  • Geography
  • & More

Try Free

Buyer(S) 1

Buyer

Strongbridge Biopharma

Trevose, Pennsylvania, United States
Category Company
Founded 1996
Sector Life Science
Revenue 31M USD (2020)
DESCRIPTION

Strongbridge Biopharma is a global commercial-stage biopharmaceutical company focused on the development and commercialization of therapies for rare diseases with significant unmet needs. Strongbridge's first commercial product is KEVEYIS® (dichlorphenamide), the first and only FDA-approved treatment for hyperkalemic, hypokalemic, and related variants of Primary Periodic Paralysis. Strongbridge Biopharma was founded in 1996 and is based in Trevose, Pennsylvania.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
State: Pennsylvania M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2016 M&A 1 of 1
Size (of disclosed) 1 of 1

Seller(S) 1

SELLER

Taro Pharmaceutical Industries

Haifa Bay, Israel
Category Company
Founded 1950
Sector Life Science
Employees1,455
Revenue 561M USD (2022)
DESCRIPTION

Taro Pharmaceutical Industries is a manufacturer and developer of generic drugs and pharmaceutical components. Taro Pharmaceutical Industries was founded in 1950 and is based in Haifa, Israel.

DEAL STATS #
Overall 1 of 1
Sector: Life Science M&A 1 of 1
Type: Divestiture M&A Deals 1 of 1
State: Pennsylvania M&A 1 of 1
Country: United States M&A 1 of 1
Year: 2016 M&A 1 of 1
Size (of disclosed) 1 of 1
FOLLOWING DEAL
DATE TARGET DEAL TYPE VALUE
2022-02-22 Alchemee

El Segundo, California, United States

Alchemee offers a mixture of science, expertise, and support that empowers customers with confidence. Through one-of-a-kind expert-designed formulas and positive guidance, the company provides solutions that are as effective as they are transformative. Alchemee is based in El Segundo, California.

Buy -
Mergr

Solution for

Product

Company

Legal